Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4611]

AACR 2018: Crizotinib yielded a high objective response rate for adult patients with ALK-positive inflammatory myofibroblastic tumour

AACR 2018: Crizotinib yielded a high objective response rate for adult patients with ALK-positive inflammatory...

A novel precision cancer model opens doors to personalised cancer treatment

A novel precision cancer model opens doors to personalised cancer treatment

'Killer' kidney cancers identified by studying their evolution

'Killer' kidney cancers identified by studying their evolution

Discovery of 4 subtypes of melanoma points to new treatment approaches

Discovery of 4 subtypes of melanoma points to new treatment approaches

One Million Genomes declaration ‘a huge leap forward’ in cancer

One Million Genomes declaration ‘a huge leap forward’ in cancer

Novel combination therapy effective for NRAS mutant and therapy resistant melanoma

Novel combination therapy effective for NRAS mutant and therapy resistant melanoma

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor breast cancer therapy

RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor breast cancer therapy

Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer

Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer

Further evidence that immunotherapy provides a long-term survival benefit for lung cancer patients

Further evidence that immunotherapy provides a long-term survival benefit for lung cancer patients

More from ecancer